Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06952517 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea
A Phase 2 study of Papulopustular Rosacea and Papular-pustular Rosacea, sponsored by Narrows Institute for Biomedical Research.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06952517 is a Phase 2 study of Papulopustular Rosacea and Papular-pustular Rosacea that is actively recruiting participants, run by Narrows Institute for Biomedical Research. The registered enrollment target is 20 participants, below the 278-participant average among 11 other Papulopustular Rosacea trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06952517, a Phase 2 study of Papulopustular Rosacea and Papular-pustular Rosacea, is actively recruiting participants, sponsored by Narrows Institute for Biomedical Research.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
To demonstrate the efficacy of Clascoterone cream 1% in reducing the size of sebaceous glands in study participants with acneiform rosacea.
Conditions Studied
Interventions
- DRUG Clascoterone Cream 1%
Study Locations (1)
New York
- New York Harbor VA Brooklyn Campus - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-03-14 |
| Est. Completion | 2025-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06952517
The ClinicalTrials.gov registry entry for NCT06952517 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 278-participant average among 11 other Papulopustular Rosacea trials with a reported enrollment target (93% lower). The listed sponsor is Narrows Institute for Biomedical Research, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Papulopustular Rosacea appearing as the primary indexed condition, and to 1 intervention - of which Clascoterone Cream 1% is the first listed.
NCT06952517 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06952517 about?
NCT06952517 is a clinical study titled "Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea". To demonstrate the efficacy of Clascoterone cream 1% in reducing the size of sebaceous glands in study participants with acneiform rosacea.
What is the current status of trial NCT06952517?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-03-14. Estimated completion is 2025-09-30.
What conditions does trial NCT06952517 study?
This clinical trial studies the following conditions: Papulopustular Rosacea, Papular-pustular Rosacea, Papulopustular Rosacea (PPR).
What interventions are being tested in trial NCT06952517?
The interventions under investigation include: Clascoterone Cream 1% (DRUG).
Who is sponsoring clinical trial NCT06952517?
This trial is sponsored by Narrows Institute for Biomedical Research, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06952517 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Papulopustular Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Twelve Week Safety and Efficacy Study in Rosacea
COMPLETED · Phase 2
-
Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
COMPLETED · Phase 2
-
Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties
COMPLETED · Phase 1
-
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
COMPLETED · Phase 3
-
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
COMPLETED · NA
-
Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.